BIO-key International reported total revenues of $5.5M for the nine months ended September 30, 2026, an increase from $4.9M in the prior year period, driven by higher license fees. Despite the revenue growth, the company incurred a net loss available to common stockholders of $6.2M, significantly impacted by a $4.5M deemed dividend related to a warrant inducement.
Bio-Key is pivoting to a high-margin software model, achieving 90% gross margins and debt-free status while leveraging Middle East expansion and agentic AI authentication.
BIO-key International reported Q3 2026 financial results, highlighted by a 39% increase in software license fee revenue to $1.3 million and a gross margin improvement to 90%. The company narrowed its quarterly net loss to $0.89 million and retired its remaining outstanding debt, leaving the firm effectively debt-free.
Term
Q3 2026
“Our Q3’26 results reflect the building strength of our core software business. Software license fee revenue grew 39% in Q3’26, offsetting variability in our more episodic hardware and services revenue and lifting gross margin to 90% from 77% a year ago.”
Mike DePasquale, CEO
“Year to date we have grown revenue by 14%, reduced our net loss by 42% and we retired our remaining note outstanding leaving us effectively debt free.”
BIO-key International reported the final voting results from its 2026 Annual Meeting of Stockholders, which concluded on October 30, 2026. Stockholders approved Proposal 4, authorizing the issuance of up to 1,236,668 shares of common stock upon the exercise of warrants from an August 2026 inducement transaction to comply with Nasdaq Listing Rule 5635(d).